ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead Widens Licensing Scope

by Jean-François Tremblay
February 2, 2015 | APPEARED IN VOLUME 93, ISSUE 5

Gilead Sciences has expanded the terms of a hepatitis C drug licensing deal with Indian generic drug producers to include GS-5816, an investigational compound that is undergoing Phase III clinical studies. The agreement also adds Biocon to the list of licensees, upping to eight the number of Indian drug companies allowed to produce and sell generic versions of Sovaldi, Gilead’s blockbuster hepatitis C drug, in 91 countries. Widening of the licensing deal comes just after the Indian patent office ruled that Sovaldi is not innovative enough to warrant patent protection. But Gilead tells C&EN that this rejection applies only to the metabolites of Sovaldi, not the main patent for the drug, which is still pending.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment